Epicardio is a MedEd/MedTech company founded in 2011 and headquartered in the United Kingdom. The company's flagship product, Epicardio Simulation™, is a cloud-based real-time 3D electromechanical simulation designed to help users master the complexities of the heart. It has been validated and is utilized by prestigious medical schools such as Oxford, Cambridge, Karolinska, as well as industry partners including Schiller, Medtronic, Boston Scientific, and Abbott.
Epicardio's focus is on developing a world-class range of intelligent simulation software for medical eTraining and eDiagnosis support, catering to multiple international markets. The company aims to become a global leader in simulation-based medical eTraining and eDiagnosis support, with the goal of improving access, reducing costs, and minimizing patient risks.
Epicardio is dedicated to creating a first-class working environment, and is open to discussing opportunities with potential partners and investors. For further information or to explore opportunities with Epicardio, interested parties can reach out via email at contact (at) epicardio (dot) com.
There is no investment information
No recent news or press coverage available for Epicardio.